Diabetic Foot Ulcers Pipeline Review, H2 2015
Summary
Global Markets Directs, Diabetic Foot Ulcers Pipeline Review, H2 2015, provides an overview of the Diabetic Foot Ulcerss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Diabetic Foot Ulcers and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Diabetic Foot Ulcers pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Diabetic Foot Ulcers Overview 11
Therapeutics Development 12
Pipeline Products for Diabetic Foot Ulcers - Overview 12
Pipeline Products for Diabetic Foot Ulcers - Comparative Analysis 13
Diabetic Foot Ulcers - Therapeutics under Development by Companies 14
Diabetic Foot Ulcers - Therapeutics under Investigation by Universities/Institutes 17
Diabetic Foot Ulcers - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Diabetic Foot Ulcers - Products under Development by Companies 21
Diabetic Foot Ulcers - Products under Investigation by Universities/Institutes 23
Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 24
Adocia 24
Aprogen, Inc. 25
Bayer AG 26
CardioVascular BioTherapeutics, Inc. 27
Celgene Corporation 28
CoDa Therapeutics, Inc. 29
CytoTools AG 30
Dipexium Pharmaceuticals LLC 31
EyeGene, Inc. 32
FirstString Research, Inc. 33
GlaxoSmithKline Plc 34
Human Stem Cells Institute 35
Innovaxis 36
Izun Pharmaceuticals Corporation 37
Karyopharm Therapeutics, Inc. 38
Lytix Biopharma AS 39
MediaPharma s.r.l. 40
MediWound Ltd. 41
NovaLead Pharma Pvt. Ltd. 42
Oneness Biotech Co., Ltd. 43
Osiris Therapeutics, Inc. 44
Plurogen Therapeutics, Inc. 45
Sanofi 46
Stratatech Corporation 47
TechnoPhage SA 48
TGV-Laboratories 49
Theravasc, Inc. 50
Tissue Med Biosciences 51
USV Limited 52
Diabetic Foot Ulcers - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Target 54
Assessment by Mechanism of Action 56
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
ALLO-ASC - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
AP-102 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
APO-2 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
becaplermin - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Biochaperone PDGF-BB - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural ulcer - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
CL-05 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CODA-001 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CVBT-141B - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Cyndacel-M - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
daprodustat - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Drug for Diabetic Foot Ulcer - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
EG-Decorin - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
epidermal growth factor biosimilar - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
EscharEx - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
esmolol hydrochloride - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Granexin - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Heberprot-P - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
IMSP-001 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
IZN-6D4 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
LTX-109 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
MPHE-001A - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
MT-003 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Mul-1867 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Neovasculgen - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Nu-2 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Nu-3 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
ON-101 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
OTI-1501 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
PDA-002 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
pexiganan acetate - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
PluroGel N - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Recombinant Erythropoetin for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
selinexor - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
sodium nitrite SR - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
TMBP-3 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
TP-102 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Vivefoot - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Diabetic Foot Ulcers - Recent Pipeline Updates 120
Diabetic Foot Ulcers - Dormant Projects 139
Diabetic Foot Ulcers - Discontinued Products 141
Diabetic Foot Ulcers - Product Development Milestones 142
Featured News & Press Releases 142
Oct 13, 2015: Izun Pharmaceuticals Announces Positive Results from Phase 2 Randomized Trial in Diabetic Foot Ulcers 142
Oct 06, 2015: Osiris Announces Initiation of a Phase III Trial for a New Investigational Drug, OTI-15-01, for the Treatment of Chronic Diabetic Foot Wounds 142
Oct 01, 2015: Dipexium Pharmaceuticals Reaches 50% Enrollment in Second Pivotal Phase 3 Clinical Trial 143
Sep 21, 2015: Dipexium Pharmaceuticals Presents Locilex Microbiology Data at ICAAC/ICC 2015 Conference 143
Aug 20, 2015: Dipexium Pharmaceuticals Surpasses Treatment Of 50% Of Subjects In Pivotal Phase 3 Clinical Trial 144
Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results 144
Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications 145
Feb 25, 2015: Dipexium Pharmaceuticals Passes 25% Enrollment in Locilex Pivotal Phase 3 Clinical Trials 146
Feb 17, 2015: Dipexium Pharmaceuticals Announces Successful Completion and Initial Results of Phase 1 Skin Sensitization Trial of Locilex 146
Nov 17, 2014: Clinical Development Program for the Wound Healing Drug DermaPro Now Extended To US Pharmaceuticals Market 147
Appendix 148
Methodology 148
Coverage 148
Secondary Research 148
Primary Research 148
Expert Panel Validation 148
Contact Us 148
Disclaimer 149
List Of Tables
Number of Products under Development for Diabetic Foot Ulcers, H2 2015 12
Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2015 13
Number of Products under Development by Companies, H2 2015 15
Number of Products under Development by Companies, H2 2015 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Late Stage Development, H2 2015 18
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Development, H2 2015 20
Products under Development by Companies, H2 2015 21
Products under Development by Companies, H2 2015 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2015 23
Diabetic Foot Ulcers - Pipeline by Adocia, H2 2015 24
Diabetic Foot Ulcers - Pipeline by Aprogen, Inc., H2 2015 25
Diabetic Foot Ulcers - Pipeline by Bayer AG, H2 2015 26
Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2015 27
Diabetic Foot Ulcers - Pipeline by Celgene Corporation, H2 2015 28
Diabetic Foot Ulcers - Pipeline by CoDa Therapeutics, Inc., H2 2015 29
Diabetic Foot Ulcers - Pipeline by CytoTools AG, H2 2015 30
Diabetic Foot Ulcers - Pipeline by Dipexium Pharmaceuticals LLC, H2 2015 31
Diabetic Foot Ulcers - Pipeline by EyeGene, Inc., H2 2015 32
Diabetic Foot Ulcers - Pipeline by FirstString Research, Inc., H2 2015 33
Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H2 2015 34
Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H2 2015 35
Diabetic Foot Ulcers - Pipeline by Innovaxis, H2 2015 36
Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corporation, H2 2015 37
Diabetic Foot Ulcers - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 38
Diabetic Foot Ulcers - Pipeline by Lytix Biopharma AS, H2 2015 39
Diabetic Foot Ulcers - Pipeline by MediaPharma s.r.l., H2 2015 40
Diabetic Foot Ulcers - Pipeline by MediWound Ltd., H2 2015 41
Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2015 42
Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co., Ltd., H2 2015 43
Diabetic Foot Ulcers - Pipeline by Osiris Therapeutics, Inc., H2 2015 44
Diabetic Foot Ulcers - Pipeline by Plurogen Therapeutics, Inc., H2 2015 45
Diabetic Foot Ulcers - Pipeline by Sanofi, H2 2015 46
Diabetic Foot Ulcers - Pipeline by Stratatech Corporation, H2 2015 47
Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H2 2015 48
Diabetic Foot Ulcers - Pipeline by TGV-Laboratories, H2 2015 49
Diabetic Foot Ulcers - Pipeline by Theravasc, Inc., H2 2015 50
Diabetic Foot Ulcers - Pipeline by Tissue Med Biosciences, H2 2015 51
Diabetic Foot Ulcers - Pipeline by USV Limited, H2 2015 52
Assessment by Monotherapy Products, H2 2015 53
Number of Products by Stage and Target, H2 2015 55
Number of Products by Stage and Mechanism of Action, H2 2015 57
Number of Products by Stage and Route of Administration, H2 2015 59
Number of Products by Stage and Molecule Type, H2 2015 61
Diabetic Foot Ulcers Therapeutics - Recent Pipeline Updates, H2 2015 120
Diabetic Foot Ulcers - Dormant Projects, H2 2015 139
Diabetic Foot Ulcers - Dormant Projects (Contd..1), H2 2015 140
Diabetic Foot Ulcers - Discontinued Products, H2 2015 141
List Of Figures
List of Figures
Number of Products under Development for Diabetic Foot Ulcers, H2 2015 12
Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2015 13
Number of Products under Development by Companies, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 18
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Products, H2 2015 20
Assessment by Monotherapy Products, H2 2015 53
Number of Products by Top 10 Targets, H2 2015 54
Number of Products by Stage and Top 10 Targets, H2 2015 54
Number of Products by Top 10 Mechanism of Actions, H2 2015 56
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 56
Number of Products by Top 10 Routes of Administration, H2 2015 58
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 58
Number of Products by Top 10 Molecule Types, H2 2015 60
Number of Products by Stage and Top 10 Molecule Types, H2 2015 60
